Corcept Therapeutics Incorporated
Corcept Therapeutics is a U.S.-based commercial-stage pharmaceutical company focused on medicines that modulate cortisol, with its core marketed product Korlym for patients with hypercortisolism, also known as Cushing’s syndrome. The company also sells an authorized generic version of Korlym in the United States, which broadened its commercial footprint while pressuring average selling prices. Beyond its commercial franchise, Corcept is building a pipeline of selective cortisol modulators for endocrine, oncologic, metabolic and neurologic disorders, including relacorilant, dazucorilant and other proprietary compounds. Its business model combines specialty drug commercialization, physician-focused sales, specialty pharmacy distribution and ongoing clinical development funded largely by product revenue.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueMarketed therapies sold in the U.S. for hypercortisolism, including branded Korlym and its authorized generic.
Selective cortisol modulators in development for endocrine, neurologic, metabolic and oncology indications.
Specialty pharmacy coordination, co-pay support and charitable assistance programs that support access to therapy.
Customers
Corcept’s direct customers are physicians treating patients with hypercortisolism, since the company’s sales force calls on endocrinologists and other specialists who diagnose and manage Cushing’s syndrome. The end users are patients with severe cortisol-related disease, but access is mediated through specialty pharmacies, distributors and payer reimbursement systems. A meaningful part of the commercial model depends on commercial insurers, Medicare, Medicaid and other payors that determine coverage, rebates and patient out-of-pocket costs. The company also relies on independent charitable foundations and patient support programs to help financially needy patients obtain therapy. On the development side, its clinical programs serve investigators, trial sites and CROs rather than commercial buyers.
Specialists who prescribe Korlym or the generic version based on clinical need and disease severity.
Patients with severe hypercortisolism who use the product and often need access support to afford treatment.
Channel partners that dispense, package and deliver the product and manage logistics.
Insurers and public programs that determine reimbursement, rebates and patient affordability.
CROs, investigators and trial sites that support development of relacorilant, dazucorilant and other candidates.
Strategy
Corcept’s strategy is to defend and expand its cortisol-modulation franchise while advancing a broader pipeline of selective cortisol modulators. In the near term, that means maximizing uptake of Korlym and the authorized generic through physician education, specialty pharmacy execution and patient access support. The company is also investing heavily in R&D to move relacorilant, dazucorilant and other compounds through clinical trials, aiming to create follow-on indications beyond hypercortisolism. Because the business is funded by product revenue, maintaining commercial momentum while controlling supply-chain and reimbursement friction is central to sustaining pipeline investment. The company’s strategic position depends on converting its scientific focus on cortisol biology into both durable commercial sales and new label opportunities.
Current revenue funds the business, so Corcept must preserve prescribing, access and channel execution despite generic competition and pricing pressure.
New indications are needed to diversify the company beyond a single commercial disease area and create longer-term growth.
Specialty drugs depend on reimbursement, affordability and channel reliability, which directly affect realized revenue.
Geography
Corcept’s commercial revenue is concentrated in the United States, where it markets Korlym and the authorized generic version. The company’s current operating model is therefore highly exposed to U.S. reimbursement policy, specialty pharmacy execution and domestic regulatory scrutiny. Its manufacturing is outsourced to contract manufacturers, including suppliers of the active pharmaceutical ingredient mifepristone and tablet/bottling services, which creates supply-chain dependence rather than owned production capacity. The pipeline has broader geographic intellectual property coverage, but the disclosed commercial business is primarily U.S.-based. As a result, geography matters less as a sales diversification story and more as a concentration risk in one healthcare system.
Risks
Corcept is exposed to concentration risk because essentially all commercial revenue comes from one disease area and one U.S. product family, making the business sensitive to prescribing trends, reimbursement and competitive launches. The company specifically cites generic competition for Korlym, public perception and legal restrictions around mifepristone, and changes in drug pricing or coverage policy as threats to sales. Its reliance on contract manufacturers, specialty pharmacies and distributors creates operational risk if any vendor fails to meet demand or transfer services smoothly. More broadly, specialty pharmaceutical companies face regulatory scrutiny, rebate pressure, patient affordability challenges and clinical development risk, especially when the pipeline is still in trial stages. Corcept also faces IT and data-security risk because its operations depend on protected patient, physician and commercial information.
- Generic erosion of KorlymImpact: HighLikelihood: High
A lower-priced generic version can shift volume away from branded product and compress average selling price.
Exposure: Core commercial franchise
- Reimbursement and pricing pressureImpact: HighLikelihood: High
Government and commercial payors can reduce net realized price through rebates, coverage limits and formulary controls.
Exposure: Net product revenue
- Mifepristone regulatory and reputational riskImpact: HighLikelihood: Low
Public and legislative scrutiny of mifepristone, even outside hypercortisolism use, may limit prescribing or access.
Exposure: Commercial demand
- Vendor and supply-chain dependenceImpact: MediumLikelihood: Medium
The company relies on third parties for API, tableting, packaging and specialty pharmacy services.
Exposure: Product availability and continuity
- Clinical development uncertaintyImpact: MediumLikelihood: Medium
Pipeline candidates may fail in trials or not achieve regulatory approval, limiting future growth options.
Exposure: Pipeline valuation
Accounting
Judgemental itemsRevenue is recorded net of estimated rebates, chargebacks, co-pay assistance, distributor discounts and returns, so estimation accuracy directly affects reported sales.
Impact: Can materially change quarterly revenue and gross margin
Most development spending is expensed as incurred, so trial timing drives operating expense volatility.
Impact: Affects operating loss/profit and comparability across periods
Purchased API and outsourced production can require write-downs if demand or manufacturing plans change.
Impact: Can affect cost of sales and inventory valuation
Specialty pharmacy and distributor transitions can shift shipments and returns between periods.
Impact: Creates seasonality and period-to-period revenue noise
Similar listed companies
Publicly listed companies with a comparable business focus.
Xeris Biopharma Holdings, Inc.
XERS · Pharmaceutical Preparations
CorMedix Inc.
CRMD · Pharmaceutical Preparations
Rezolute, Inc.
RZLT · Pharmaceutical Preparations
Soligenix, Inc
SNGX · Pharmaceutical Preparations
BioCryst Pharmaceuticals, Inc
BCRX · Biological Products, (No Diagnostic Substances)
Biocryst Pharmaceuticals is a U.S.-based biotechnology company focused on rare diseases, with its core commercial product ORLADEYO for hereditary angioedema (HAE).
Crinetics Pharmaceuticals, Inc.
Pharmaceutical Preparations
Crinetics Pharmaceuticals is a U.S.-based biopharmaceutical company focused on endocrine diseases and endocrine-related tumors.
Last updated: 24/09/2026